AUCTORES
Globalize your Research

Biotechnology and Bioprocessing
Mohamed Moumaris *

Open Access

Editorial

Unlocking the Potential: Overcoming Challenges in CAR-T Cell Therapy for Cancer Treatment

Mohamed Moumaris

Institute of Science and Technology, Research and Development Company, France.

***Corresponding Author:** Mohamed Moumaris, Institute of Science and Technology, Research and Development Company, France.

Received date: January 30, 2024; Accepted date: February 15, 2024; Published date: February 29, 2024

Citation: Mohamed Moumaris, (2024), Unlocking the Potential: Overcoming Challenges in CAR-T Cell Therapy for Cancer Treatment, *J, Biotechnology and Bioprocessing* 5(2); **DOI:10.31579/2766-2314/136**

Copyright: © 2024, Mohamed Moumaris. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abbreviations

CAR: Chimeric antigen receptor

Editorial

Recent years have seen significant progress in cancer treatment, notably through innovations like immunotherapy and genetic modifications. However, the diverse nature of cancer cells, especially in solid tumors, remains a significant hurdle. While successes have been notable in blood-related cancers, extending therapies like CAR T cell therapy to solid tumors is complex. CAR T therapy is effective against B-cell malignancies and faces challenges in solid tumors due to the need for specific cancer antigens. This editorial examines CAR T therapy, particularly in solid tumors, highlighting the urgent need for new treatment approaches. Targeting antigens like B7-H3 shows promise, but obstacles remain, including understanding the tumor microenvironment and identifying suitable antigens.

Although medical progress, exemplified by advancements like immunotherapy and genetic modifications, has been remarkable, the formidable obstacle of cancer cell diversity still poses a significant challenge to effective cancer treatment. Most research has focused on blood-related cancers with limited application for solid tumors [1, 2]. CAR T therapy has demonstrated remarkable success in treating B-cell-related cancers, especially those focused on CD19. Extending CAR T cell therapy to solid tumors remains challenging due to the need for specific cancer antigens distinct from healthy tissues [3, 4]. CAR T cell therapy is promising for cancer treatment, particularly in pediatric solid tumors. This approach targets specific tumor antigens, such as B7-H3 [5, 6].

CAR T cells are used for treating B-cell malignancies, employing advanced genetic editing techniques to reduce the risk of graft-versus-host disease (Figure 1). CAR T cell therapy is an innovative approach for hematological cancers, especially those related to B-cells, modifying a patient's T-cells to express CARs targeting cancer cell markers [7, 8]. Allogeneic natural killer cells (NKTs) are an alternative to CAR T therapy. They have non-immunogenic properties, tumor-targeting with macrophages and specific CD8 T cells. CD19-targeted CAR T cell therapy has revolutionized the treatment of lymphoid malignancies, especially B cell lymphoma, with approved products and ongoing research exploring their application in various treatment stages, including central nervous system lymphoma treatment [9, 10].

CAR-T cell research primarily focuses on specific cells, such as lymphoma cells. However, it has broader applications, including enhancing regulatory T cells (Tregs) with CARs for antigen tolerance. This approach holds promise for organ transplantation and conditions like lupus [10, 11]. Challenges faced by CAR-T therapy to treat solid tumors are due to the immunosuppressive tumor microenvironment and limited target antigens. Researchers work on developing practical CAR T strategies for effective tumor treatment [12, 13].

Recent medical advancements have propelled cancer treatment forward, yet the diverse nature of cancer cells, especially in solid tumors, presents a significant challenge. While past research predominantly focused on blood-related cancers, breakthroughs like CAR T cell therapy have shown remarkable success in treating B-cell malignancies, hinting at broader applications in pediatric solid tumors. CAR T therapy's precision in targeting specific tumor antigens, such as B7-H3, underscores its potential as a potent oncological tool. Moreover, utilizing advanced genetic editing techniques to mitigate risks like graft-versus-host disease demonstrates the ongoing refinement of this therapy [14-34].

Despite persistent challenges in navigating the immunosuppressive tumor microenvironment and identifying suitable target antigens for solid tumors, ongoing research endeavors offer hope for overcoming these obstacles. Alternative approaches like allogeneic natural killer cells and expanding CAR-T therapy to include regulatory T cells show the rapid evolution of cancer treatment strategies. As we approach a new era in oncology characterized by personalized and targeted therapies, collaboration, innovation, and determination are key. Continuous dedication and interdisciplinary teamwork of CAR T cell therapy and similar treatments offer new hope for transforming cancer care, benefiting patients and caregivers in their relentless battle against the disease.



Figure 1: CAR-T cell

Figure 1: CAR-T cell therapy involves a multi-step process: (1) T cells are extracted from the patient, (2) A gene encoding a chimeric antigen receptor is introduced into these T cells, granting them the ability to target a specific antigen, (3) The genetically modified T cells are infused into the patient's body.

Acknowledgments

The author acknowledges Mrs. Norri Zahra and Mr. Regragui Moumaris. The author thinks Nisen Abuaf and Said Youssouf Chanfi (Sorbonne University). The author thinks Jean-Michel Bretagne (Assistance Puplique - Hôpitaux de Paris). The author thinks Marie-Hélène Maës and Monique Abuaf (16th district of Paris).

References

1. Luksik A.S., Yazigi E., Shah P. (2023). Jackson C.M. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers (Basel). V. 15, №5. - P.1414.
2. Miliotou A.N., Papadopoulou L.C. (2018). CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr Pharm Biotechnol. V.19, №1. - P.5-18.
3. Arabi F., Torabi-Rahvar M., Shariati A., Ahmadbeigi N., Naderi M. (2018). Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Exp Cell Res. V.369, №1. - P.1-10.
4. S. Vivekanandhan et al. (2023). Immunotherapies in rare cancers. Mol Cancer. V.22, №1. - P.23.
5. P. Rasic et al. (2023). Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. Molecules. V.28, №8. - P.3356.
6. Argemi J., Ponz-Sarvise M., Sangro B. (2022). Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. Adv Cancer Res. V.156, №367. -P.413.
7. W. Qasim. (2023). Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. Blood. V.141, №8. - P. 835-845.
8. Ramesh P., Hui H.Y.L, Brownrigg L.M, Fuller K.A, Erber W.N. (2023). Chimeric antigen receptor T-cells: Properties, production, and quality control. Int J Lab Hematol. V.45, №4. - P.425-435.
9. Courtney A.N, Tian G., Metelitsa L.S. (2023). Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. V.141, №8. - P.869-876.
10. Boardman A.P, Salles G. (2023). CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. V.41 Suppl 1(Suppl 1). - P.112-118.
11. Y.R. Mohseni et al. (2020). The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Front Immunol. V.11. - P.1608.
12. Z. Zhou et al. (2022). Chimeric antigen receptor T cells applied to solid tumors. Front Immunol. V.13. - P.984864.
13. W. Sang et al. (2020). Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. V.9, №16. - P.5827-5838.
14. M. Moumaris. (2024). Lyme Disease: A Zoonosis Tick-Borne Borrelia Bacterium [4/4]. Int J Zoo Animal Biol. V.7, №1. - P.1-3.
15. M. Moumaris. (2023). Revolutionizing Malaria Research: CRISPR unveils New Frontiers. J Biotechnology and Bioprocessing. V.4, №5. - P.2766-2314.
16. M. Moumaris. (2023). Lyme Disease: A Zoonosis Tick-Borne Borrelia Bacterium [3/4]. Int J Zoo Animal Biol. V.6, №4. - P.1-3.
17. M. Moumaris. (2023). Lyme Disease: A Zoonosis Tick-Borne Borrelia Bacterium [2/4]. Int J Zoo Animal Biol. V.6, №2. - P.1-4.
18. M. Moumaris. (2022). Lyme Disease: A Zoonosis Tick-Borne Borrelia Bacterium [1/4]. Int J Zoo Animal Biol. V.5, №6. - P.1-3.
19. Moumaris M., Bretagne J.M., Abuaf N. (2020). Nanomedical Devices and Cancer Theranostics. The Open Nanomedicine and Nanotechnology Journal. V. 6. - P.1-11.
20. Moumaris M., Bretagne J.M., Abuaf N. (2019). Biological Membranes and Malaria-Parasites. The Open Parasitology Journal. V. 7. - P. 1-18.
21. Moumaris M., Bretagne J.M., Abuaf N. (2018). Hospital Engineering of Medical Devices in France. The Open Medical Devices Journal. V. 6. - P. 10-20.
22. Moumaris M., Rajoely B., Abuaf N. (2015). Fluorescein Isothiocyanate-Dextran can track Apoptosis and Necrosis induced by heat shock of Peripheral Blood Mononuclear

Cells and HeLa Cells. Open Biological Sciences Journal. V. 1. - P.7-15.

23. Moumaris M., Rajoely B., Abuaf N. (2012). The Naïve B Cells are the Lymphocytes with the Highest Anionic Phospholipid Binding Ratios. The Open Immunology Journal. V. 5. - P.27-35.
24. M. Moumaris. (2007). Magnetic resonance imaging at the Hôtel-Dieu of Paris. Paris-Descartes University, France.
25. M. Moumaris. (2005). Identification of a new molecule to monitor apoptosis. Sorbonne-Paris-Nord University, France.
26. M. Moumaris. (2003). Biomedical research, the law of bioethics relating to the donation and use of elements and products of the human body. Paris-Descartes University, France.
27. Moumaris M., Abuaf N. (2002). Use of labeled dextran for in-vitro assessment of increased cell permeability, cell death and apoptosis. Bulletin officiel de la propriété industrielle (Brevet n°00/09235). V. 2811682. - P.A3.
28. Moumaris M., Benoliel S. Rouquette A.M., Rajoely B., Abuaf N. (2000). Phospholipid binding proteins on the plasma membrane of lymphocytes. J Autoimmun V.15, №2. - P.81-271, A5-95, i-xi, A33.
29. M. Moumaris et al. (1999). Characterization of B-cell adhering to the lamellar phospholipids. French Congress of Antiphospholipid Antibody, Paris.
30. M. Moumaris. (1996). Membranes érythrocytaires dans le paludisme: modèle d'étude: Souris- Plasmodium berghei anka. Université Pierre et Marie Curie, Paris, France.
31. M. Moumaris et al. (1995) Effect of Fatty Acid Treatment in Cerebral Malaria-Susceptible and Nonsusceptible Strains of Mice. The Journal of Parasitology. V.81, №6. - P.997-999.
32. Sabolovic D., Moumaris M., Miltgen F., Sestier C., Halbreich A. (1995). A subpopulation of red blood cells induced by bleeding or mosquito sucking. Chinese National Congress of Medical Biophysics, Shanghai.
33. Sabolovic D., Moumaris M., Miltgen F., Sestier C., Halbreich A. (1995). Characterisation of subpopulation of red blood cells as a preferential target for malaria invasion. French Congress of Electrophoresis, Cell Electrophoresis, Pastor Institute, Paris. V. 19, №7. - P.1215-1219.
34. M. Moumaris. (1992). Lyme disease: Serological study. University of Orleans, France.

This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: **Submit Manuscript**

DOI: 10.31579/ 2766-2314/136

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more https://www.auctoresonline.org/journals/biotechnology-and-bioprocessing